Clinical trials: Cancer of Skin
Estrogen Receptor Negative, Estrogen Receptor Positive
Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer
This phase II trial studies the side effects and how well giving paclitaxel and cyclophosphamide with or without trastuzumab before surgery works in treating patients with previously untreated breast cancer.
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, HER2/Neu Positive
- Trial name
- NCT01750073
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis
- Where
- 4 sites in United States
- Volunteers
- 92 people
- Sponsor
- University of Nebraska
Breast Neoplasms
Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer
RATIONALE: Educational programs may improve coping and quality of life in younger women who have recently been treated for early-stage breast cancer.
- Trial name
- NCT00416572
- Testing
- Education Intervention, Nutrition Education Intervention
- Volunteers
- 252 people
- Sponsor
- Carnegie Mellon University
Melanoma
Does the Aid of MelaFind Affect Clinical Management Decisions
The objective of this study is to determine and compare the performance of dermatologists (in Germany) on the excision decision against the performance of MelaFind, a non-invasive and objective multi-spectral computer vision…
- Trial name
- NCT01387581
- Where
- United States
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- MELA Sciences, Inc.
Breast Carcinoma Metastatic in the Brain, Estrogen Receptor Negative
Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis
The purpose of this study is to evaluate if the study drug palbociclib has anti-tumor activity against the breast cancer that has spread to the brain and also to determine the overall radiographic response rate in the CNS.
- Conditions
- Breast Carcinoma Metastatic in the Brain, Estrogen Receptor Negative, HER2/Neu Negative, HER2/Neu Positive
- Trial name
- NCT02774681
- Testing
- Cognitive Assessment, Palbociclib, Quality-of-Life Assessment
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
Melanoma
Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients
The purpose of this study is to determine whether vaccination with tumor antigenic peptides and both IMP321/LAG-3 and Montanide adjuvants can induce an immune response in melanoma patients and to assess the safety and…
- Trial name
- LAG-3/IMP321 (NCT01308294)
- Testing
- 2 vaccine injections in 1 limb, 2 vaccine injections in distinct limbs, 2 "vaccine injections" in distinct limbs
- Where
- Switzerland
- Volunteers
- 16 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Non Small Cell Lung Cancer, Urothelial Cancer
Study of INCB086550 in Select Solid Tumors
An open-label, nonrandomized study to evaluate the efficacy and safety of INCB086550, a first-in-class oral inhibitor of PD-L1, as initial immune checkpoint inhibitor therapy in participants with select solid tumors
- Conditions
- Non Small Cell Lung Cancer, Urothelial Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT04629339
- Testing
- INCB086550
- Where
- 20 sites in Bulgaria, Hungary and 3 more
- Volunteers
- 16 people
- Sponsor
- Incyte Corporation
Breast Cancer
Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer
This research study is studying a drug called Abemaciclib as a possible treatment for have metastatic triple-negative type of breast cancer.
- Trial name
- NCT03130439
- Testing
- Abemaciclib
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer, Metastases
Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
The purpose of this clinical research study is to learn if BMS-247550 added to the approved therapy of capecitabine is better than capecitabine alone in shrinking or slowing the growth of the cancer in women with metastatic…
- Trial name
- NCT00080301
- Testing
- Ixabepilone + Capecitabine, Capecitabine
- Where
- 127 sites in United States, Argentina and 20 more
- Volunteers
- 752 people
- Sponsor
- R-Pharm
Melanoma (Skin)
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma
This randomized phase II trial is studying how well carboplatin, paclitaxel, and bevacizumab work when given with or without everolimus in treating patients with malignant melanoma that has spread from where it started to other…
- Trial name
- NCT00976573
- Testing
- bevacizumab, carboplatin, everolimus
- Where
- 310 sites in United States
- Volunteers
- 149 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer
Primary Objectives: Dose Escalation: To assess the incidence rate of dose-limiting toxicity (DLT) and to determine the maximum tolerated dose (MTD) as well as the recommended dose (RD) of amcenestrant administered as monotherapy…
- Trial name
- AMEERA-1 (NCT03284957)
- Testing
- Amcenestrant, Palbociclib, Alpelisib
- Where
- 25 sites in United States, Belgium and 8 more
- Volunteers
- 136 people
- Sponsor
- Sanofi
Solid Tumor, Solid Carcinoma
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
The purpose of this study is to find out whether the study drug benralizumab is a safe treatment that can reduce the skin side effects caused by cancer treatment by reducing the level of eosinophils in your blood.
- Conditions
- Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Hematologic Malignancy
- Trial name
- NCT04552288
- Testing
- Benralizumab
- Where
- 5 sites in United States
- Volunteers
- 51 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Actinic Keratoses
Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp
The aim of this study is to test the safety, tolerability and efficacy of field-directed photodynamic therapy (PDT) with 10% aminolevulinic acid gel (Ameluz®, BF-200 ALA) in combination with one of the narrow spectrum red light…
- Trial name
- NCT05662202
- Testing
- BF-200 ALA and red light LED lamp, Vehicle and red light LED lamp
- Where
- 14 sites in United States
- Volunteers
- 172 people
- Sponsor
- Biofrontera Inc.
Melanoma Stage III, Melanoma Stage IV
Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma
The purpose of this study is to test the effects of anti-PI-1 inhibitor (TSR-042) or anti-PD-1/anti-TIM-3 combination (TSR-042 / TSR-022) in patients with operable melanoma.
- Trial name
- NCT04139902
- Testing
- Dostarlimab (TSR-042) (singly), Dostarlimab (TSR-042) and TSR-022 (combination)
- Where
- 5 sites in United States
- Volunteers
- 58 people
- Sponsor
- Diwakar Davar
Fibrosis
Trental & Vitamin E for Radiation-Induced Fibrosis
This study seeks to determine if a combination of Trental and Vitamin E prevents the development of radiation fibrosis in women treated with radiation for the definitive management of their breast cancer.
- Trial name
- NCT00583700
- Testing
- Pentoxifylline, Vitamin E
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of Iowa
Actinic Keratoses
Actinic Keratoses Treatment With Metvix® in Combination With Light
The main objective of this study is to compare efficacy and safety of Metvix® natural daylight photodynamic therapy with those of Metvix® conventional photodynamic therapy in subjects with mild actinic keratoses (intra-individual…
- Trial name
- NCT02373371
- Testing
- Metvix®, Photodynamic Therapy Blue light, Photodynamic Therapy Daylight
- Where
- France
- Volunteers
- 26 people
- Sponsor
- University Hospital, Limoges
Breast Cancer
Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies
The purpose of this study is to provide eribulin to patients with advanced breast cancer who have no other treatment options and therapy is requested by an Investigator.
- Trial name
- NCT01142661
- Testing
- Eribulin Mesylate
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Eisai Inc.
Arthralgia, Breast Cancer
Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment
This randomized phase III trial studies testosterone to see how well it works compared to placebo in treating postmenopausal patients with arthralgia (joint pain) caused by anastrozole or letrozole.
- Conditions
- Arthralgia, Breast Cancer, Hot Flashes, Musculoskeletal Complications
- Trial name
- NCT01573442
- Testing
- testosterone
- Where
- 529 sites in United States, Puerto Rico
- Volunteers
- 227 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Neoplasms, Breast
Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer
The purpose of this study is to determine the efficacy and safety of an oral dual tyrosine kinase inhibitor (GW572016) in combination with paclitaxel compared to paclitaxel alone in first line advanced or metastatic breast cancer.
- Trial name
- NCT00075270
- Testing
- Paclitaxel, GW572016 (Lapatinib)
- Where
- 177 sites in United States, Argentina and 23 more
- Volunteers
- 580 people
- Sponsor
- GlaxoSmithKline
Melanoma
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)
The primary purpose of this study is to compare pembrolizumab/vibostolimab to pembrolizumab with respect to recurrence-free survival (RFS).
- Trial name
- NCT05665595
- Testing
- Pembrolizumab/Vibostolimab, Pembrolizumab
- Where
- 205 sites in United States, Argentina and 24 more
- Volunteers
- 1,594 people
- Sponsor
- Merck Sharp & Dohme LLC
Melanoma, Malignant Melanoma
Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma
Background: This study will use cells called DMF5 to treat patients with metastatic melanoma (melanoma that has spread beyond the primary tumor site).
- Conditions
- Melanoma, Malignant Melanoma, Melanoma, Experimental
- Trial name
- NCT00924001
- Testing
- DMF5 Melanoma Reactive TIL, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.